JP7138046B2 - 二特異性抗体基幹 - Google Patents

二特異性抗体基幹 Download PDF

Info

Publication number
JP7138046B2
JP7138046B2 JP2018531487A JP2018531487A JP7138046B2 JP 7138046 B2 JP7138046 B2 JP 7138046B2 JP 2018531487 A JP2018531487 A JP 2018531487A JP 2018531487 A JP2018531487 A JP 2018531487A JP 7138046 B2 JP7138046 B2 JP 7138046B2
Authority
JP
Japan
Prior art keywords
domain
amino acid
acid sequence
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018531487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502694A (ja
JP2019502694A5 (https=
Inventor
マーティン プレイアー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2019502694A publication Critical patent/JP2019502694A/ja
Publication of JP2019502694A5 publication Critical patent/JP2019502694A5/ja
Priority to JP2021092180A priority Critical patent/JP2021121642A/ja
Application granted granted Critical
Publication of JP7138046B2 publication Critical patent/JP7138046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018531487A 2015-12-18 2016-12-15 二特異性抗体基幹 Active JP7138046B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021092180A JP2021121642A (ja) 2015-12-18 2021-06-01 二特異性抗体基幹

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269664P 2015-12-18 2015-12-18
US62/269,664 2015-12-18
PCT/US2016/066865 WO2017106462A1 (en) 2015-12-18 2016-12-15 Bispecific antibody platform

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021092180A Division JP2021121642A (ja) 2015-12-18 2021-06-01 二特異性抗体基幹

Publications (3)

Publication Number Publication Date
JP2019502694A JP2019502694A (ja) 2019-01-31
JP2019502694A5 JP2019502694A5 (https=) 2020-01-16
JP7138046B2 true JP7138046B2 (ja) 2022-09-15

Family

ID=57681809

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018531487A Active JP7138046B2 (ja) 2015-12-18 2016-12-15 二特異性抗体基幹
JP2021092180A Pending JP2021121642A (ja) 2015-12-18 2021-06-01 二特異性抗体基幹

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021092180A Pending JP2021121642A (ja) 2015-12-18 2021-06-01 二特異性抗体基幹

Country Status (9)

Country Link
US (1) US11447575B2 (https=)
EP (1) EP3389710A1 (https=)
JP (2) JP7138046B2 (https=)
KR (1) KR20180100136A (https=)
CN (1) CN108601830B (https=)
AU (1) AU2016370821A1 (https=)
CA (1) CA3008840A1 (https=)
MA (1) MA44054A (https=)
WO (1) WO2017106462A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
KR102794369B1 (ko) 2017-08-01 2025-04-15 에이비 테라퓨틱스 인코퍼레이티드 이중특이 항체 및 그의 용도
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
US20220089704A1 (en) 2018-10-29 2022-03-24 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
US20220227827A1 (en) * 2019-03-25 2022-07-21 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
US12077603B2 (en) * 2019-08-15 2024-09-03 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
US20220306760A1 (en) * 2019-08-23 2022-09-29 Igm Biosciences, Inc. Igm glycovariants
MX2022003507A (es) * 2019-09-25 2022-04-25 Univ Stuttgart Modulos de union que comprenden dominios ehd2 modificados.
WO2021139758A1 (zh) * 2020-01-09 2021-07-15 江苏恒瑞医药股份有限公司 新型多肽复合物
CN113307879A (zh) * 2020-02-27 2021-08-27 启愈生物技术(上海)有限公司 一种taa/ctla-4/il15三功能融合蛋白及其应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022096704A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
CA3219388A1 (en) * 2021-05-14 2022-11-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
JP2025532897A (ja) * 2022-09-28 2025-10-03 ドレン バイオ， インコーポレイテッド 多重特異性抗体及びその使用方法
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
WO2026044055A1 (en) 2024-08-23 2026-02-26 Modernatx, Inc. Muc16 binding molecules, nucleic acids encoding same, and methods of use
WO2026075820A1 (en) 2024-10-03 2026-04-09 Modernatx, Inc. 4-1bb binding molecules, nucleic acids encoding same, and methods of use
CN121148519B (zh) * 2025-11-18 2026-02-13 西北农林科技大学 基于计算模拟辅助的双特异性抗体分子设计与优化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514405A (ja) 2012-04-16 2015-05-21 ウニヴェルズィテート シュトゥットガルト 二重特異性を有する融合タンパク質産生のための共有結合したホモ二量体化モジュールとしてのＩｇＭおよびＩｇＥ重鎖ドメイン２

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
MX342034B (es) * 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
MX2014014162A (es) * 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
WO2016087650A1 (en) * 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
EP3897851A2 (en) * 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514405A (ja) 2012-04-16 2015-05-21 ウニヴェルズィテート シュトゥットガルト 二重特異性を有する融合タンパク質産生のための共有結合したホモ二量体化モジュールとしてのＩｇＭおよびＩｇＥ重鎖ドメイン２

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Molecular Cancer Therapeutics, 2014, Vol.13, No.1, p.101-111
Protein Engineering, Design & Selection, 2012, Vol.25, No.10, p.603-612

Also Published As

Publication number Publication date
JP2021121642A (ja) 2021-08-26
JP2019502694A (ja) 2019-01-31
CN108601830B (zh) 2023-02-03
KR20180100136A (ko) 2018-09-07
CA3008840A1 (en) 2017-06-22
US20190048098A1 (en) 2019-02-14
AU2016370821A1 (en) 2018-07-12
EP3389710A1 (en) 2018-10-24
MA44054A (fr) 2018-10-24
WO2017106462A1 (en) 2017-06-22
US11447575B2 (en) 2022-09-20
CN108601830A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
JP7138046B2 (ja) 二特異性抗体基幹
US11649295B2 (en) Asymmetric multispecific antibodies
CN107207592B (zh) 结构域交换的抗体
JP2019528051A (ja) 修飾抗原結合Ｆａｂ断片及びこれを含む抗原結合分子
WO2013064701A2 (en) Bispecific antibodies and methods for isolating same
WO2014150973A1 (en) Methods for producing fabs and bi-specific antibodies
WO2017134440A2 (en) Heterodimers and purification thereof
EP4303231A1 (en) Bispecific antibody
KR20220017909A (ko) 단백질 다량체화를 위한 변이체 도메인 및 그의 분리
EP3728328A1 (en) Bispecific antigen binding construct
TW202311295A (zh) 一種抗原結合分子
JP2022518282A5 (https=)
JP7785258B2 (ja) 多量体ＩｇＡ抗体の作製法及び多重特異性多量体ＩｇＡ抗体
JP2024500354A (ja) ヘテロ二量体化のための直交変異
EA051713B1 (ru) Биспецифическое антитело
JP2026064000A (ja) 抗原結合分子
TW202330607A (zh) 特異性結合ｃｇｒｐ和ｐａｃａｐ的抗原結合分子及其醫藥用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220905

R150 Certificate of patent or registration of utility model

Ref document number: 7138046

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150